Skip to main content
. 2019 Jan;37(1):11–34. doi: 10.2337/cd18-0105

TABLE 5.

Drug-Specific and Patient Factors to Consider When Selecting Antihyperglycemic Treatment in Adults With Type 2 Diabetes

Inline graphic

*For agent-specific dosing recommendations, please refer to the manufacturers’ prescribing information.

†FDA approved for CVD benefit.

CHF, congestive heart failure; CV, cardiovascular; DPP-4, dipeptidyl peptidase 4; DKA, diabetic ketoacidosis; GLP-1 RAs, GLP-1 receptor agonists; NASH, nonalcoholic steatohepatitis; SQ, subcutaneous; T2DM, type 2 diabetes.